These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21602447)

  • 1. Number and brightness image analysis reveals ATF-induced dimerization kinetics of uPAR in the cell membrane.
    Hellriegel C; Caiolfa VR; Corti V; Sidenius N; Zamai M
    FASEB J; 2011 Sep; 25(9):2883-97. PubMed ID: 21602447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monomer dimer dynamics and distribution of GPI-anchored uPAR are determined by cell surface protein assemblies.
    Caiolfa VR; Zamai M; Malengo G; Andolfo A; Madsen CD; Sutin J; Digman MA; Gratton E; Blasi F; Sidenius N
    J Cell Biol; 2007 Dec; 179(5):1067-82. PubMed ID: 18056417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorescence correlation spectroscopy and photon counting histogram on membrane proteins: functional dynamics of the glycosylphosphatidylinositol-anchored urokinase plasminogen activator receptor.
    Malengo G; Andolfo A; Sidenius N; Gratton E; Zamai M; Caiolfa VR
    J Biomed Opt; 2008; 13(3):031215. PubMed ID: 18601539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
    Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
    J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
    Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
    ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitronectin binding to urokinase receptor in human breast cancer.
    Carriero MV; Del Vecchio S; Franco P; Potena MI; Chiaradonna F; Botti G; Stoppelli MP; Salvatore M
    Clin Cancer Res; 1997 Aug; 3(8):1299-308. PubMed ID: 9815812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application limits and data correction in number of molecules and brightness analysis.
    Trullo A; Corti V; Arza E; Caiolfa VR; Zamai M
    Microsc Res Tech; 2013 Nov; 76(11):1135-46. PubMed ID: 23934660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation.
    Zhao B; Gandhi S; Yuan C; Luo Z; Li R; Gårdsvoll H; de Lorenzi V; Sidenius N; Huang M; Ploug M
    J Mol Biol; 2015 Mar; 427(6 Pt B):1389-1403. PubMed ID: 25659907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single amino acid substitutions in the chemotactic sequence of urokinase receptor modulate cell migration and invasion.
    Bifulco K; Longanesi-Cattani I; Franco P; Pavone V; Mugione P; Di Carluccio G; Masucci MT; Arra C; Pirozzi G; Stoppelli MP; Carriero MV
    PLoS One; 2012; 7(9):e44806. PubMed ID: 23049759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor.
    Schiller HB; Szekeres A; Binder BR; Stockinger H; Leksa V
    Mol Biol Cell; 2009 Feb; 20(3):745-56. PubMed ID: 19037107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
    Vines DJ; Lee SW; Dichek DA; Ellis V
    J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-detector number and brightness analysis reveals spatio-temporal oligomerization of proteins in living cells.
    Fukushima R; Yamamoto J; Ishikawa H; Kinjo M
    Methods; 2018 May; 140-141():161-171. PubMed ID: 29572069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system.
    Stahl A; Mueller BM
    Int J Cancer; 1997 Mar; 71(1):116-22. PubMed ID: 9096674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative regulation of urokinase receptor activity by a GPI-specific phospholipase C in breast cancer cells.
    van Veen M; Matas-Rico E; van de Wetering K; Leyton-Puig D; Kedziora KM; De Lorenzi V; Stijf-Bultsma Y; van den Broek B; Jalink K; Sidenius N; Perrakis A; Moolenaar WH
    Elife; 2017 Aug; 6():. PubMed ID: 28849762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.
    Czekay RP; Kuemmel TA; Orlando RA; Farquhar MG
    Mol Biol Cell; 2001 May; 12(5):1467-79. PubMed ID: 11359936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.
    Chavakis T; Kanse SM; Yutzy B; Lijnen HR; Preissner KT
    Blood; 1998 Apr; 91(7):2305-12. PubMed ID: 9516128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
    Salasznyk RM; Zappala M; Zheng M; Yu L; Wilkins-Port C; McKeown-Longo PJ
    Matrix Biol; 2007 Jun; 26(5):359-70. PubMed ID: 17344041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
    Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
    Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structure of the urokinase receptor in a ligand-free form.
    Xu X; Gårdsvoll H; Yuan C; Lin L; Ploug M; Huang M
    J Mol Biol; 2012 Mar; 416(5):629-41. PubMed ID: 22285761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocytosis of urokinase-plasminogen activator inhibitor type 1 complexes bound to a chimeric transmembrane urokinase receptor.
    Li H; Kuo A; Kochan J; Strickland D; Kariko K; Barnathan ES; Cines DB
    J Biol Chem; 1994 Mar; 269(11):8153-8. PubMed ID: 7510679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.